cas 1996-44-7|| where to buy 2,4-difluorobenzene-1-thiol

製品名:2,4-difluorobenzene-1-thiol

IUPAC Name:2,4-difluorobenzene-1-thiol

包装単位	有効在庫	価格（USD）
CM379550-10g	in stock	șǯ
CM379550-25g	in stock	ƞňǯ
CM379550-100g	in stock	Ǖňƞ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1996-44-7 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1996-44-7; 分子式:C6H4F2S; 融点:-; SMILESコード:FC1=CC(F)=C(S)C=C1; 密度:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Neflamapimod; Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.